Patent intelligence · US
US 9856241
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
Patent details — US 9856241
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 2, 2018
- Expiration
- Dec 28, 2037
- Applicant
- Karyopharm Therapeutics Inc.
- Claims
- 16
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P1/16
Quick answer
US 9856241 (Substituted benzofuranyl and benzoxazolyl compounds and uses thereof) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Jan 2, 2018. Expires Dec 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Karyopharm Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P1/16, A61P1/18, A61P11/00
More from Karyopharm Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12371420
Polymorphs of Selinexor
granted -
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12318386
Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
granted -
US 12291508
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11945794
Nuclear transport modulators and uses thereof
granted -
US 11807629
Polymorphs of Selinexor
granted -
US 11787771
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11753401
Polymorphs of Selinexor
granted
Related coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Frequently asked questions
What is US patent 9856241?
US 9856241 (Substituted benzofuranyl and benzoxazolyl compounds and uses thereof) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Jan 2, 2018. Expires Dec 28, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9856241?
Karyopharm Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 9856241 expire?
Our index shows an expiration date of Dec 28, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.